Elanco Animal Health (ELAN) Stock: Buy, Sell, or Hold?
ELAN - Elanco Animal Health Incorporated Common Stock
$22.14
0.37 (1.70%)
▲
5d:
-0.76%
30d:
-10.29%
90d:
-11.9%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 06, 2026
Get Alerted When ELAN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ELAN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ELAN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$39.70
Based on 8.6% avg growth
INTRINSIC VALUE TODAY
$24.65
10.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ELAN is currently trading at $22.14, which is considered oversold relative to its 30-day fair value range of $22.37 to $24.27. From a valuation perspective, the stock is trading at a discount (Forward PE: 17.2) compared to its historical average (20.5). Remarkably, the market is currently pricing in an annual earnings decline of 5.7% over the next few years. This pessimistic expectation contrasts with the company's recent 440.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ELAN is showing sideways momentum. The price is currently testing key support at $21.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ELAN scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $31.00 (+40.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ELAN is showing sideways momentum. The price is currently testing key support at $21.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ELAN scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $31.00 (+40.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$22.37 -
$24.27
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
Protect Your Profits
Holding ELAN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (71/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.0% below Wall St target ($31.00)
- CAUTION: Bottoming setup, but lagging the sector by 23% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$22.37 -
$24.27
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$21.62
Resistance Level
$23.39
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.23
Wall Street Target
$31.00
(+40.0%)
Revenue Growth (YoY)
10.2%
Earnings Growth (YoY)
440.5%
Profit Margin
-4.0%
Valuation Discount vs History
-5.7% cheaper
PE vs Historical
17.2 vs 20.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.7%
(market-implied from PE analysis)
1-Year Target
$20.88
(-6%)
2-Year Target
$19.69
(-11%)
3-Year Target
$18.57
(-16%)
3-Yr Target (if PE normalizes)
(PE: 17→21)
$22.09
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 13.2%)
$38.04
(+72%)
Base:
(SPY PE: 17.2, Growth: 13.2%)
$32.13
(+45%)
Bear:
(PE: 14.6, Growth: 13.2%)
$27.31
(+23%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.2 to 20.5
Stabilization Target:
$26.34
(+19.0%)
PE Expansion Potential:
+19.0%
Share & Embed Analysis
Last updated: October 03, 2026 6:33 PM ET
Data refreshes hourly during market hours. Next update: 7:33 PM
Data refreshes hourly during market hours. Next update: 7:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELAN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
Advanced ELAN Option Strategies
Professional options setups generated by AI based on today's ELAN price and gamma walls.
